The prostate cancer experts at Medivation are getting into the hot field of checkpoint inhibitors for cancer, agreeing to pay Israel’s CureTech as much as $335 million for the full rights to a promising Phase II asset.

…read more

Source: Medivation buys into PD-1, picking up where Teva left off


0 No comments